Exploiting research conducted at Kyoto Prefecture University of Medicine, Aurion Biotech is focusing on therapies that can restore vision.

Aurion Biotech, a US-based ophthalmology-focused regenerative therapies developer based on work at Kyoto Prefecture University of Medicine, obtained $120m in funding yesterday led by Deerfield Management. Eye care products developer Alcon took part in the round, as did Petrichor Healthcare Capital Management, Flying L Partners, KKR-backed Falcon Vision and Visionary Ventures. Aurion Biotech’s initial programme…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.